Cost-effectiveness and budget impact analysis of PPV23 vaccination for the Malaysian Hajj pilgrims.

Farhana Aminuddin, Nur Amalina Zaimi, Mohd Shaiful Jefri Mohd Nor Sham Kunusagaran, Mohd Shahri Bahari, Nor Zam Azihan Mohd Hassan
Author Information
  1. Farhana Aminuddin: Institute for Health Systems Research, Ministry of Health Malaysia, Shah Alam, Malaysia. ORCID
  2. Nur Amalina Zaimi: Institute for Health Systems Research, Ministry of Health Malaysia, Shah Alam, Malaysia.
  3. Mohd Shaiful Jefri Mohd Nor Sham Kunusagaran: Institute for Health Systems Research, Ministry of Health Malaysia, Shah Alam, Malaysia.
  4. Mohd Shahri Bahari: Institute for Health Systems Research, Ministry of Health Malaysia, Shah Alam, Malaysia.
  5. Nor Zam Azihan Mohd Hassan: Institute for Health Systems Research, Ministry of Health Malaysia, Shah Alam, Malaysia.

Abstract

The potential occurrence of disease outbreaks during the hajj season is of great concern due to extreme congestion in a confined space. This promotes the acquisition, spread and transmission of pathogenic microorganisms and pneumococcal disease are one of the most frequent infections among Hajj pilgrims. This study aimed to assess the cost-effectiveness and budget impact of introducing the PPV23 to Malaysian Hajj pilgrims. A decision tree framework with a 1-year cycle length was adapted to evaluate the cost-effectiveness of a PPV23 vaccination program with no vaccination. The cost information was retrieved from the Lembaga Tabung Haji Malaysia (LTH) database. Vaccine effectiveness was based on the locally published data and the disease incidence specifically related to Streptococcus pneumoniae was based on a literature search. Analyses were conducted from the perspective of the provider: Ministry of Health and LTH Malaysia. The incremental cost-effectiveness ratios (ICER), cases averted, and net cost savings were estimated. Findings from this study showed that PPV23 vaccination for Malaysian Hajj pilgrims was cost-effective. The PPV23 vaccination programme has an ICER of MYR -449.3 (US$-110.95) per case averted. Based on the national threshold value of US$6,200-US$8,900 per capita, the base-case result shows that introduction of the PPV23 vaccine for Malaysian Hajj pilgrims is very cost-effective. Sensitivity analysis revealed parameters related to annual incidence and hospitalised cost of septicemia and disease without vaccination as the key drivers of the model outputs. Compared with no vaccination, the inclusion of PPV23 vaccination for Malaysian Hajj pilgrims was projected to result in a net cost saving of MYR59.6 million and 109,996 cases averted over 5 years period. The PPV23 vaccination program could substantially offer additional benefits in reducing the pneumococcal disease burden and healthcare cost. This could be of help for policymakers to consider the implementation of PPV23 vaccination for Malaysian performing hajj.

References

  1. N S W Public Health Bull. 2011 Nov;22(9-10):179-95 [PMID: 22060056]
  2. Int J Infect Dis. 2018 Apr;69:68-74 [PMID: 29474989]
  3. BMC Infect Dis. 2013 Feb 27;13:108 [PMID: 23446215]
  4. Stat Methods Med Res. 2015 Dec;24(6):615-34 [PMID: 21930515]
  5. Gac Sanit. 2002 Sep-Oct;16(5):392-400 [PMID: 12372184]
  6. Clin Infect Dis. 2014 Feb;58(4):e106-9 [PMID: 24248810]
  7. J Infect Public Health. 2012 Mar;5(1):22-34 [PMID: 22341840]
  8. Saudi Med J. 2003 Oct;24(10):1073-6 [PMID: 14578971]
  9. Ann Thorac Med. 2016 Apr-Jun;11(2):93-102 [PMID: 27168856]
  10. Value Health Reg Issues. 2014 May;3:146-155 [PMID: 29702920]
  11. Travel Med Infect Dis. 2009 Jul;7(4):247-52 [PMID: 19717109]
  12. Clin Infect Dis. 2015 May 15;60(10):1472-80 [PMID: 25669354]
  13. BMC Fam Pract. 2015 Oct 28;16:158 [PMID: 26510703]
  14. Int J Antimicrob Agents. 2002 Feb;19(2):85-93 [PMID: 11850160]
  15. Health Technol Assess. 2009 Jun;13(29):iii, ix-xi, 1-61 [PMID: 19500484]
  16. Int J Infect Dis. 2014 Oct;27:26-31 [PMID: 25128639]
  17. Vaccine. 2020 Jul 6;38(32):4988-4995 [PMID: 32536548]
  18. Vaccine. 2011 Oct 13;29(44):7644-50 [PMID: 21854825]
  19. Science. 2009 Nov 13;326(5955):938-40 [PMID: 19933105]
  20. Hum Vaccin. 2011 Oct;7(10):1037-47 [PMID: 21941088]
  21. Lancet. 2006 Mar 25;367(9515):1008-15 [PMID: 16564364]
  22. N S W Public Health Bull. 2012 Dec;23(9-10):179-86 [PMID: 23442995]
  23. Lancet. 2014 Jun 14;383(9934):2073-2082 [PMID: 24857703]
  24. Ann Intern Med. 1986 Jan;104(1):79-86 [PMID: 3079638]
  25. Semin Respir Crit Care Med. 2009 Apr;30(2):189-209 [PMID: 19296419]
  26. Epidemiol Infect. 2008 Mar;136(3):360-9 [PMID: 17445314]
  27. Value Health. 2017 Sep;20(8):1131-1138 [PMID: 28964445]
  28. Pharmacoeconomics. 2014 Jan;32(1):29-45 [PMID: 24288207]
  29. Pediatr Infect Dis J. 2016 Nov;35(11):e353-e361 [PMID: 27753771]
  30. Wkly Epidemiol Rec. 2016 Jul 1;91(26-27):331-5 [PMID: 27372990]
  31. J Travel Med. 2010 Mar-Apr;17(2):82-8 [PMID: 20412173]
  32. Hum Vaccin Immunother. 2016;12(2):326-30 [PMID: 26176306]
  33. Cost Eff Resour Alloc. 2017 May 5;15:7 [PMID: 28484344]
  34. BMC Infect Dis. 2012 May 16;12:117 [PMID: 22591189]
  35. Hum Vaccin. 2011 Apr;7(4):441-50 [PMID: 21441776]
  36. J Travel Med. 2004 Mar-Apr;11(2):82-6 [PMID: 15109471]
  37. Ann Saudi Med. 2005 Mar-Apr;25(2):94-9 [PMID: 15977684]
  38. J Infect Public Health. 2017 May - Jun;10(3):277-286 [PMID: 27262693]
  39. JAMA. 1997 Oct 22-29;278(16):1333-9 [PMID: 9343464]
  40. J Infect Public Health. 2013 Dec;6(6):401-9 [PMID: 23999349]
  41. Pharmacoeconomics. 2000 Jun;17(6):591-601 [PMID: 10977396]
  42. PLoS One. 2018 Feb 9;13(2):e0192640 [PMID: 29425249]

MeSH Term

Cost-Benefit Analysis
Humans
Immunization Programs
Islam
Malaysia
Male
Pneumococcal Vaccines
Pneumonia, Pneumococcal
Streptococcus pneumoniae
Travel
Vaccination

Chemicals

Pneumococcal Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinationPPV23HajjpilgrimsMalaysiandiseasecostcost-effectivenessavertedhajjpneumococcalstudybudgetimpactprogramMalaysiaLTHbasedincidencerelatedICERcasesnetcost-effectiveperresultanalysispotentialoccurrenceoutbreaksseasongreatconcerndueextremecongestionconfinedspacepromotesacquisitionspreadtransmissionpathogenicmicroorganismsonefrequentinfectionsamongaimedassessintroducingdecisiontreeframework1-yearcyclelengthadaptedevaluateinformationretrievedLembagaTabungHajidatabaseVaccineeffectivenesslocallypublisheddataspecificallyStreptococcuspneumoniaeliteraturesearchAnalysesconductedperspectiveprovider:MinistryHealthincrementalratiossavingsestimatedFindingsshowedprogrammeMYR-4493US$-11095caseBasednationalthresholdvalueUS$6200-US$8900capitabase-caseshowsintroductionvaccineSensitivityrevealedparametersannualhospitalisedsepticemiawithoutkeydriversmodeloutputsComparedinclusionprojectedsavingMYR596million1099965yearsperiodsubstantiallyofferadditionalbenefitsreducingburdenhealthcarehelppolicymakersconsiderimplementationperformingCost-effectiveness

Similar Articles

Cited By